Abcam founder Jonathan Milner opposes Danaher buyout; First Wave tries to find new life in Sanofi drug
Abcam’s founder Jonathan Milner plans to vote against Danaher’s $5.7 billion acquisition of the company, he announced Thursday.
Milner owns …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
